This protocol has the aim of monitoring in vivo myelin changes (demyelination and remyelination) by positron emission tomography (PET) imaging in an animal model of multiple sclerosis.
Multiple sclerosis (MS) is a neuroinflammatory disease with expanding axonal and neuronal degeneration and demyelination in the central nervous system, leading to motor dysfunctions, psychical disability, and cognitive impairment during MS progression. Positron emission tomography (PET) is an imaging technique able to quantify in vivo cellular and molecular alterations.
Radiotracers with affinity to intact myelin can be used for in vivo imaging of myelin content changes over time. It is possible to detect either an increase or decrease in myelin content, what means this imaging technique can detect demyelination and remyelination processes of the central nervous system. In this protocol we demonstrate how to use PET imaging to detect myelin changes in the lysolecithin rat model, which is a model of focal demyelination lesion (induced by stereotactic injection) (i.e., a model of multiple sclerosis disease). 11C-PIB PET imaging was performed at baseline, and 1 week and 4 weeks after stereotaxic injection of lysolecithin 1% in the right striatum (4 µL) and corpus callosum (3 µL) of the rat brain, allowing quantification of focal demyelination (injection site after 1 week) and the remyelination process (injection site at 4 weeks).
Myelin PET imaging is an interesting tool for monitoring in vivo changes in myelin content which could be useful for monitoring demyelinating disease progression and therapeutic response.
Multiple sclerosis (MS) is a neuroinflammatory disease that affects the central nervous system, characterized by inflammation, demyelination, and axonal loss1. The prognosis of this disease is variable even with advances in treatment, and it is one of the most common causes of neurological deficits in young people1. The diagnosis of MS is based on the criteria of clinical manifestation and visualization of characteristic lesions by magnetic resonance imaging (MRI)2,3.
Positron emission tomography (PET) can be a useful tool for in vivo monitoring of MS progression and therapeutic effects. The Pittsburgh compound B radiotracer (PIB) labeled with carbon-11 (11C-PIB) is widely used to quantify β-amyloid plaques; however, in the last decade, it has been studied to quantify myelin content and show dynamic demyelination and remyelination4,5,6.
Different amyloid PET tracers (11C-PIB, 18F-florbetaben,18F-florbetapir, 18F-flutemetamol) can be used to quantify myelin and provide important information about disease progression and therapeutic response, allowing identification of demyelination and remyelination processes, without the interference of neuroinflammation, which can occur with conventional magnetic resonance images (MRI)7. Amyloid PET imaging showed decreased tracer uptake in active MS patients compared to non-active patients which could be explained by early white matter damage in the active patients8. Lower amyloid tracer uptake was also associated with cognitive decline in a follow-up study, showing this technique to be a valuable tool for studying the pathophysiology of the disease and clinical outcomes9.
The lysolecithin (LPC) rat model is a chemical induced model of multiple sclerosis, where the injected toxin, LPC, induces a high response of macrophages that results in increased inflammation and, consequently, demyelination10,11. The demyelination is rapidly reversed, in approximately 4 weeks, which makes this a good model for evaluating demyelination and remyelination processes in rodents. This model has already been evaluated using PET imaging, with good results and correlation with post-mortem essays12.
Here we present the protocol for myelin PET imaging with 11C-PIB in the lysolecithin rat model, showing this imaging technique to be a useful tool for in vivo measurement of myelin content.
All procedures were conducted in accordance with the guidelines of the National Council for the control of Animal Experimentation (CONCEA, Brazil) and were approved by the Ethics Committee for Animal Research of the Medical School of the University of Sao Paulo (CEUA-FMUSP, Brazil – protocol number: 25/15).
NOTE: In this protocol, we show how to induce a lysolecithin rat model of multiple sclerosis and how to acquire and analyze the myelin PET images.
1. Lysolecithin solution preparation
2. Lysolecithin rat model – Stereotaxic surgery
3. PET acquisition
4. Image Analysis
NOTE: Perform image analysis using dedicated image analysis software. In the current protocol the demonstration uses a specific software program, but if it is not available, other options can be used.
Figure 1 shows illustrative 11C-PIB PET images with myelin changes over time. In the baseline scan, no differences can be seen in myelin content (i.e., no demyelination is present). In the 1-week time-point image, it is possible to see the focal demyelinated lesion (in the right hemisphere) as indicated by the white arrow. Images are presented in the 3 anatomical planes (coronal, axial, and sagittal) and it is possible to identify the demyelinated lesion in all of them. The 1-week image is the illustration of a well delimited lesion at the injection site, representing the correct model induction and image detection. In the 4 weeks image, no lesion is visible anymore, indicating that remyelination has occurred and myelin content is back to normal (or close to it).
The representative graphs show the quantification of the images of 4 animals in the 3 different time points. The first graph shows the results from the quantification of the lesion (manual VOI) to contralateral side ratio demonstrating more focal myelin changes, where the lysolecithin injection was performed. The second graph shows the same quantification, but in the striatum (injected striatum to contralateral ratio) and in this case the difference is not statistically significant, which can be explained by the small sample size and because the VOI is bigger and the radioactivity concentration is measured not only where the lysolecithin was injected.
Differences between groups were analyzed by the Kruskal Wallis test, followed by Dunn´s test for multiple comparisons and the results are presented as mean ± SD. In the lesion VOI (H = 7.063; P=0.017), in the 1-week image, the tracer uptake ratio (0.90±0.07) was 16% lower than baseline (1.07±0.06), with statistical significance (p=0.024). No significant differences were found in the 4-week image (1.01±0.06).
In the striatum, no statistical differences were found (H =1.412; P=0.5393). The uptake ratios for the images were 1.07±0.07 for baseline, 1.02±0.07 for 1 week, and 1.01±0.08 for 4 weeks.
The third graph (bottom line, left graph) presents the quantification of the contralateral striatum (non-injected side). In this graph it is possible to observe that there was no difference (P=9397) among time points, meaning that the variation in the injected side is due to myelin changes and not due to tracer uptake variation over time.
The final graph, in the bottom right, shows the quantification of the injected site (lesion VOI) in animals where the model was not well induced (probably due to fast lysolecithin injection, wrong stereotaxic manipulation, and/or incorrect solution preparation). In this case, the lower uptake is not seen in the 1 week time point, meaning no demyelination process has occurred, and the low uptake at 4 weeks can be related to a later demyelination process or tissue damage, both situations are related to bad animal model induction. This graph was added to the protocol to exemplify the appearance of the results when the animal induction is not well performed and to emphasize the importance of each step of the protocol, from the beginning to the end. There are no differences in the tracer uptake (H = 2.745, P = 0.267) with uptake ratios of 1.06±0.05, 1.02±0.14, and 0.96±0.10 for baseline, 1 week, and 4 week PET images.
Figure 2 adds more information to the results, where Figure 2A details where the manual VOI was drawn, based on the MRI template reference and Figure 2B shows the luxol fast blue staining (for details about the luxol fast blue staining protocol, see De Paula Faria et al.13) from the injected side and non-injected side at 7 days post stereotaxic injection.
Figure 1: Illustrative 11C-PIB PET images showing images of baseline, 1 week, and 4 weeks after stereotactic injection. The graphs at the bottom of the figure represent the quantification of tracer uptake (n=4) at different time points. The first two graphs represent the uptake ratio in the injected side to contralateral side in the lesion and in the striatum in a well induced model (i.e., rats presenting lesion after lysolecithin injection). The third graph (bottom left) shows the quantification of non-injected striatum (negative control), and the final graph (bottom right) represents the 11C-PIB uptake at the injection site of animals that did not present demyelinated lesion (badly induced model). Results are presented as mean±SD. Please click here to view a larger version of this figure.
Figure 2: Lesion location details. A) Illustrative VOIs of injected side (dashed line) and non-injected side (white line) drawn manually based on the MRI template (region of corpus callosum and striatum) at 1 week post stereotactic injection. B) Luxol fast blue staining showing demyelination in the injected hemisphere compared to the non-injected side (Top: 40x magnification, bottom: 100x magnification). Please click here to view a larger version of this figure.
The biggest advantage of using the lysolecithin model to study multiple sclerosis is the fast timeline for demyelination (about 1 week) and remyelination (about 4 weeks) to occur14. This model can also be induced in mice15, however, induction in rats is more advantageous for in vivo PET imaging due to the larger size of the rat brain compared to mice.
The first step of the induction model is to be extremely cautious. This model was validated for myelin PET imaging by de Paula Faria et al.10 in 2014 and it was shown that the speed of the lysolecithin injection inside the brain is crucial for a well induced model. The injection must be performed very slowly, 1 µL each 10 min, as a way of avoiding tissue damage. The lysolecithin solution should also be prepared on the same day as the stereotactic injection, preferably just before starting the surgery procedure. If the model will be used for the first time in a research group, we recommend that the model should be validated before performing any myelin quantification by PET imaging. The validation needs to include post-mortem tissue analysis by myelin staining, for example: Luxol fast blue histology, as shown in Figure 2, and myelin basic protein (MPB) immunohistochemistry, in the different time points intended to be used in in vivo analysis. In the results section we showed a quantification of radiotracer uptake where lesion induction was not well succeeded and, therefore, the differences were not detected by 11C-PIB PET imaging.
The lesion to be quantified by this technique must be bigger than the PET scanner resolution (about 1 mm in preclinical equipment and about 5 mm in clinical equipment).
Once the model is well induced, the imaging procedure must be well planned, due to the radiotracer labeled with carbon-11, which has a short half-life of 20 minutes. The preclinical imaging laboratory personnel need to prepare all necessary material, fill the anesthesia system, check if everything is working properly, and print the forms to be completed during the experiment. The PET scanner should also be verified prior to the experiment, when all quality controls necessary in the equipment (dependent on each country) must be performed to check the scanner is well functioning. After receiving the tracer for injection, the measurement of activity must also be measured in a calibrated dose calibrator to guarantee the correct injected dose, and the information (activity in the syringe, before and after injection) written on the form, as well as the respective time when the measurement was performed. Establish which watch is going to be used, as the right time is the time on the workstation of the PET scanner, the time that will be considered in the decay correction of the images, therefore, any watches used during the experiment should be synchronized to the scanner workstation time.
During animal image acquisition, temperature and animal breathing should be monitored and the anesthesia adjusted, as necessary. Temperature is location dependent and should be adjusted for the animal well-being. After the image acquisition is finished, it is important to keep the animal on a warm pad to recover before being returned to the cage.
Image processing is crucial for getting reliable results from the experiments using PET imaging. The ideal is that the analyzer is not aware of the animal groups and/or treatment and that he/she already has experience in PET images with the PET tracer used in such a way as to guarantee perfect registration between the PET imaging and MRI template. We used the PMOD software in this protocol, but if this software is not available, alternative image quantification software can be used, although attention must be given to achieving good brain region definition and quantification. For the definition of the lesion location, extra care must be taken to ensure that the injected site is inside the drawn lesion VOI (a knowledge of rat brain anatomy is necessary).
It is important to say that myelin PET imaging can also be performed in other MS animal models, displaying unpredictable lesions, as already shown by our group in the Experimental Autoimmune Encephalomyelitis (EAE) marmoset model5. As already stated, the important parameter to consider in lesion quantification is the PET scanner resolution, which is the limitation for detection of lesions that are too small. PET imaging is a poor resolution imaging technique when compared to other techniques such as MRI, however it is a highly specific modality and, because of this, quantification of the PET images uses an anatomical template, such as the MRI, for helping to draw the region of interest, as shown in the above protocol.
Although the manual drawing of VOIs is operator dependent, it is the best option for the LPC animal model, since the lesion can be variable between animals. To diminish bias in the quantification process, it is important to perform a mirror VOI, as explained in the protocol, which will be in the same region and of the same size as the injected side. It is also important to have the stereotaxic coordinates in mind when drawing the VOI in the MRI template to guarantee that the correct brain region is considered. Using the myelin staining as a guide to identify the demyelinated area can also help in the drawing, as explained in de Paula Faria12.
The authors have nothing to disclose.
β-cube equipment (Molecubes NV, Belgium) was supported by the São Paulo Research Foundation, FAPESP – Brazil (#2018/15167-1). LES has a PhD student scholarship from FAPESP – Brazil (#2019/15654-2).
Analytical Balance | Marte | AUWZZOD | max: 220 g- min: 1 mg |
Anestesia vaporizer | Nanitech | 15800 | |
Beta-cube | Molecubes | ||
Bulldog clamp | Stoelting | 5212043P | |
clorexidine | Rioquimica | 0.5%/100 mL | |
Cotton swabs | johnson e johnson | ||
Dose calibrator | Capintech | ||
Drill | Kinzo powertools | 352901 | Model Q0M-DC3C |
Eppendorf tube | Eppendorf | 30125150 | 1.5 mL |
Eye lubricant | ADVFARMA | 30049099 | vaseline 15 g (pharmaceutical purity) |
Fine forceps | Stoelting | 52102-38P | |
Gloves | Descarpack | 212101 | 6.5 size |
Heating pad | Softhear | ||
Injection Syringe | Hamilton | 80314 | 10µ, 32ga, model 701 |
Insuline syringe | BD | 328328 | 1 mL insulin syringes with needle |
Isoflurane | Cristália | 410525 | 100 mL , concentration 1 mL/1 mL |
Ketoprofen or other analgesic | Sanofi | 100 mg/2 mL | |
lidocaine | Hipolabor | 1.1343.0102.001-5 | 2%/20mL |
L-α-Lysophosphatidylcholine from egg yolk | Sigma-aldrich | L-4129 | 25 mg – ≥99%, Type I, powder |
Needle holder | Stoelting | 5212290P | |
Oxygen | White Martins | 7782-44-7 | Compressed gas |
PMOD software | PMOD technologies | Version 4.1 | module fuse it |
Rat anesthesia mask | KOPF | Model 906 | |
Saline | Farmace | 0543325/ 14-8 | 0.9% sodium chloride for injection, 10 mL |
Scapel blades | Stoelting | 52173-10 | |
Scapel handles | Stoelting | 52171P | |
Scissor | Stoelting | 52136-50P | |
Semi-analytical Balance | Quimis | BK-3000 | max:3,100 g; min:0.2 g |
shaver | Mega profissional | AT200 model | |
Stereotactic Apparatus | KOPF | Nodel 900 | |
Universal holder with needle support | KOPF | Model 1772-F1 | Hamilton support for 5 and 10 µL |